BioTech Sales Tips: 10 Scripts for Selling Reagents, Instruments and CRO Services
Scientists don't trust salespeople. Lab managers are time-poor and sceptical of vendor claims. Here's how to sell into biotech and life sciences without getting shown the door.
Why BioTech Sales Is Different
Your Buyer Has a PhD and Will Fact-Check Everything
Life sciences buyers are trained scientists. They evaluate vendor claims the way they evaluate data — with rigour and healthy scepticism. A rep who can't speak the language of their assay format, cell line, or instrument platform gets dismissed immediately. Scientific credibility isn't a competitive differentiator in biotech sales; it's the minimum requirement to stay in the room.
Grant Cycles and Budget Windows Are Fixed
Academic and biotech lab budgets run on grant cycles — NIH R01s, project grants, industry research agreements — not financial years. There are specific windows when budget is available and windows when it's exhausted. Reps who try to push deals outside these windows stall repeatedly. The reps who understand where a lab is in its funding cycle can time proposals to available budget rather than fighting for attention when there's nothing to spend.
Trial Samples and Proof-of-Concept Experiments Close More Deals Than Demos
A scientist who has run your reagent in their own assay, with their own controls, has all the data they need to justify the purchase. A polished demo deck doesn't. In biotech and life sciences sales, the product evaluation is the sale — and the rep who puts a well-supported trial sample in the buyer's hands, with application notes and field scientist support, wins more often than the rep who perfects their pitch.
10 BioTech Sales Tips
The Scientist-Credibility Introduction
The fastest way to lose a life sciences buyer is to open with a product pitch. Scientists spend their careers filtering out vendor noise — and a generic introduction reads as exactly that. The only way to earn their attention is to demonstrate that you understand their specific research context before you say anything about what you sell. Lead with a technical question about their model system, their assay workflow, or their current approach. Then listen.
Script
"Before I get into what we offer, I want to understand what you're working on — because the only way I can tell you whether our technology is relevant is if I understand your specific model system and what you're trying to measure. What does your current [assay / workflow / instrument setup] look like?"
The "Send Me a Sample" Objection Handler
In biotech, 'send me a sample' is not a buying signal — it's a holding pattern. Labs receive dozens of samples a year that sit in the fridge untested. The rep who sends a sample and follows up in three weeks with 'did you get a chance to try it?' will wait forever. The rep who turns the sample request into a structured trial — with a defined experiment, a timeline, and a follow-up locked in before the sample ships — converts at a dramatically higher rate.
Script
"Happy to send a trial lot. To make sure it's actually useful rather than sitting in the fridge, let me suggest a slightly different approach: I'll send the sample along with the application note for your specific assay format, and we schedule a 20-minute call in three weeks to go through the data together. That way you've got FAE support if you hit any issues, and we both know whether it's a fit. Does that work?"
The Grant Cycle Alignment Play
Trying to push a deal at the wrong point in a lab's grant cycle is one of the most common reasons biotech deals stall. A researcher who is mid-grant, deep in an experiment, will not make a major purchasing decision. But a researcher who is at the start of a new grant period — with fresh budget and new objectives — is ready to hear about new technologies. The rep who asks the right question at the right time closes the timing conversation cleanly.
Script
"I know instrument and reagent budgets are often tied to grant cycles rather than calendar quarters — is your current grant running to [approximate period]? I ask because if there's budget to deploy before the cycle closes, it's usually much easier to move quickly than to restart the conversation in the next period when new priorities are competing for the same budget."
The Lab Manager Discovery Open
Lab managers are the operational backbone of a research facility — they manage ordering, vendor relationships, inventory, and protocol compliance. They are not scientists making experimental decisions, but they have significant influence over which suppliers get preferred status and which ones get squeezed on price. The discovery conversation that resonates with a lab manager focuses on protocol efficiency, reproducibility consistency, and the reduction of ordering and logistics friction.
Script
"Lab managers usually tell me the things that slow them down most aren't the big purchasing decisions — it's the day-to-day stuff: lot-to-lot consistency issues, delivery timelines that don't match experimental schedules, products that are validated on paper but perform differently in practice. Is any of that familiar, or is your current supplier setup running smoothly?"
The "We Use a Different Supplier" Objection
Incumbency in the lab is powerful — switching reagents mid-project is a genuine technical risk, and most researchers won't do it without a compelling reason. Don't argue with the existing supplier relationship. Instead, surface the pain point that almost every lab has experienced: lot-to-lot variability. A batch that didn't perform as expected, an assay that suddenly stopped working, a data point that couldn't be replicated. That's your competitive opening — not a feature comparison.
Script
"That makes sense — most labs have established suppliers for core reagents, and switching mid-project is a real risk. The question I'd ask is whether reproducibility has ever been a challenge with your current source, or whether there have been specific lots that performed better than others. Because that's usually where we find the gaps that make a data-controlled comparison worth running."
The Principal Investigator (PI) Buy-In Play
In academic and biotech labs, the Principal Investigator controls the scientific direction of the lab and, often, the budget. A lab manager can facilitate a purchase, but a PI who doesn't know your technology exists won't prioritise it. Getting PI buy-in before procurement means the decision moves on scientific merit, not administrative convenience. The conversation that works with a PI is technical, not commercial — validate their research direction before you mention your product.
Script
"I've been having a conversation with your lab manager about [product/application], but I wanted to connect with you directly because the scientific question at the centre of it is genuinely interesting. The specific challenge in [application area] that we've been addressing with labs at [reference institution] is [specific technical problem]. Is that something that comes up in your work?"
The Procurement and Compliance Objection Handler
In regulated environments — pharma R&D, clinical research, GMP manufacturing — procurement teams have legitimate quality and compliance requirements that vendors must meet before they can supply. A supplier qualification process, ISO certification check, or COA audit can add weeks to a deal timeline if the rep isn't prepared. The rep who pre-empts this conversation — and arrives at the procurement meeting already QA-ready — removes the most predictable bottleneck in regulated biotech sales.
Script
"I know in your environment, procurement isn't just about price — there's a supplier qualification process, and QA has specific requirements around certificates of analysis, lot traceability, and regulatory compliance documentation. I've come prepared: here's our current ISO certification, our COA template, and the lot-to-lot traceability documentation your QA team will ask for. What else does your qualification process require?"
The CRO (Contract Research Org) Discovery Open
CRO decisions are fundamentally about trust and risk management. The client is outsourcing experimental work — and the fears are legitimate: timeline slippage, data integrity issues, IP leakage, and the loss of direct control over critical path experiments. A CRO rep who opens with capabilities and capacity is missing the actual decision criteria. The rep who leads with timeline risk, IP protection processes, and a willingness to share a relevant project reference wins the discovery conversation.
Script
"CRO decisions usually come down to two things above everything else: timeline reliability and data you can actually publish. The fear isn't usually about scientific capability — it's about whether a delay in your critical path experiment costs you six months on a programme, or whether the data package you get back is clean enough to take to the regulator. What's the timeline pressure on this project, and what does success look like at the end of it?"
The KOL (Key Opinion Leader) Reference Play
In biotech and life sciences, peer endorsement is the single most powerful commercial tool available. A recommendation from a respected KOL — a named scientist at a leading research institution who has published results using your technology — carries more weight than any vendor claim, any sales deck, or any ROI model. The rep who can offer a direct introduction to a relevant KOL reference closes faster than the rep who relies on internal sales collateral alone.
Script
"I know in this environment, the most credible thing I can offer isn't our own data — it's a conversation with someone who's used it. We've had strong results at [institution] with [named researcher / lab group], specifically in [application area]. Would it be useful for me to make an introduction? It's a 20-minute call — they're happy to walk through exactly how they set up the assay and what the reproducibility data looked like."
The Expansion Play
The most durable biotech accounts aren't single-lab relationships — they're site agreements that span multiple labs, departments, or therapeutic programmes. But expansion doesn't happen automatically. It requires the rep to map the organisation, identify related labs with adjacent application needs, and use the success data from the first lab as the proof point. The rep who treats the first deal as a beachhead, not a destination, builds the accounts that grow year on year.
Script
"Now that we have strong data from [first lab / application], I want to ask about the broader picture. Are there other labs in the [department / site / therapeutic area] running similar assays where this would be relevant? The reason I ask is that a site agreement usually means significantly better pricing for everyone — and your [lab manager / procurement team] often prefers the simplicity of a single preferred supplier contract."
The BioTech Sales Process
BioTech deals are won at every stage — not just at close. Here's how the best life sciences reps control the process from scientific credibility to site-wide expansion.
What Separates Top BioTech Sales Reps
Life sciences is one of the most technically demanding sales environments in B2B. The reps who consistently win do these five things differently.
- ●They lead with a technical question, not a product pitch — credibility is earned before the commercial conversation starts
- ●They turn sample requests into structured trials with follow-up locked in before the sample ships
- ●They map grant cycles and propose at the right point in the funding window, not at their quarter end
- ●They pre-empt procurement and compliance objections by arriving QA-ready with COA and regulatory documentation
- ●They think in accounts, not transactions — the first lab is the beachhead for a site-wide agreement
Related Resources
Get The Futureproofed Sales Playbook — $47
The complete playbook — frameworks, scripts, and systems for every stage of the sale. Used by 500+ salespeople.
30-day money-back guarantee. Instant download.